Trending...
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Heritage at South Brunswick's Townhome Models Coming Soon!
- SprintRay Retainers Available in Allentown from Exeter Smiles
PHILADELPHIA, Oct. 16, 2020 /PRNewswire/ -- Enterin, Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of David McCullough as Chief Executive Officer.
With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes. "I am thrilled to have the opportunity to join this team that is pioneering the science behind truly innovative approaches in the treatment of neurodegenerative diseases," says McCullough.
More on The PennZone
Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."
About Enterin Inc.
Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.
More on The PennZone
For more information, please visit www.enterininc.com.
Contact
Enterin Inc.
[email protected]
Related Images
enterin-logo.jpg
Enterin Logo
SOURCE Enterin Inc.
With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes. "I am thrilled to have the opportunity to join this team that is pioneering the science behind truly innovative approaches in the treatment of neurodegenerative diseases," says McCullough.
More on The PennZone
- Cody Keller Bookkeeping Empowers Harrisburg Entrepreneurs with Stress-Free Financial Management
- Revenue Optics Ignites AI Revolution in Industrial Distribution
- Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development
- Axiros North America Announces New CEO: Gabriel Davidov
- CCHR Exposes Harms Behind Today's Mental Health Awareness Campaigns
Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."
About Enterin Inc.
Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.
More on The PennZone
- Now Is the Right Time: Kaltra Highlights Its Proven Replacement Microchannel Coils
- How to Optimize Your Website for AI Search with DeepRank AI
- New Free Science Bingo Cards Help Grade 1 Students Learn Through Play
- DeployHub Joins Catalyst Campus SDA TAP Lab
- Veterans Day 2025: Virginia Veterans Can Claim Free Words of Veterans Book Vouchers
For more information, please visit www.enterininc.com.
Contact
Enterin Inc.
[email protected]
Related Images
enterin-logo.jpg
Enterin Logo
SOURCE Enterin Inc.
Filed Under: Business
0 Comments
Latest on The PennZone
- Cerberus ODC in Collaboration with NVIDIA Launches All-American AI-RAN Stack, Enabling AI-Native 5G Today and Accelerating the Path to 6G
- National Compliance Firm issues Artificial Intelligence Policy Program for Mortgage Banking
- Pastor Darrell Armstrong Suspends Gubernatorial Campaign And Endorses Mikie Sherrill
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
- Offline Asset Protection: NJTRX Implements 98 Percent Cold Storage as Industry Faces 2 Billion USD Losses
- Thousands of Smiles, Millions of Logo Views: RoarFun Brings Emotions Into Premium Retail Spaces with Formula Simulator for Immersive Brand Activation
- Qvarz LLC Expands Global Reach with High-Precision Quartz Cuvettes and Optical Components
- $300 Million Web3 Initiative and ZIGChain Partnership Power $20 Target in Noble Capital Markets Report for SEGG Media (N A S D A Q: SEGG)
- Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
- OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
- Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
- Heritage at South Brunswick's Townhome Models Coming Soon!
- PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
- Boston Industrial Solutions Unveils New and Improved Natron® UV Screen Printing Ink
- SprintRay Retainers Available in Allentown from Exeter Smiles
- Genuine Smiles Unveils New User-Friendly Website
- Nusign Global Launch Event Concludes Successfully, Embarking on a New International Chapter